King’s College London: “From Molecules to Medicines”

News from IFAPP Academy

King’s College London: From Molecules to Medicine

King’s College London, IFAPP Academy’s academic partner, has a strong tradition in pharmaceutical science.

King’s College London has a strong tradition in pharmaceutical science, world-class pharmacology, clinical pharmacology, and therapeutics. This has led to the creation of a number of spin-out companies, including MedPharm and Proximagen Neuroscience plc.

The School of Cancer and Pharmaceutical Science was created to bring together the relevant research groupings across King’s College London.

Molecules to Medicine’s strategy is designed to capture and highlight the broad sweep of research at King’s ranging from pharmacological and chemical studies that can identify novel drug targets and new chemical entities, through formulation and drug development, to clinical trials and the use of medicines by patients. The all-embracing strategy is for researchers to work together towards the discovery of novel medicines and new formulations that can be evaluated in patients in the clinic.

To achieve this goal, and to provide focus, research activities are organized into three related themes: Drug Discovery, Medicines Development, and Medicines Use. Each of these themes includes clusters of research activity, some of which have evolved during the past decade (e.g. drug delivery, chemical biology, pharmaceutical biophysics, pharmacology), and some of which have joined King’s more recently such as enhanced activity in anticancer and anti-infective drug discovery, nanomedicines, substance abuse, health psychology, and clinical pharmacy. Researchers within and across the three themes interact both informally and via joint initiatives to promote cross-disciplinary research. For example, the drug delivery activities of Forbes, Jones, and Daily, working closely with colleagues in pharmacology (Page/Spina) have led to consortium funding and several Ph.D. studentships from the MRC to investigate the safety of nanoparticles in the airways.

This excerpt was originally published on the King’s College website at

The IFAPP Academy in partnership with King’s College London offers Academic and Professional Certification for students successfully completing the Medical Affairs in Medicines Development course. To learn about the benefits of Certification from the IFAPP Academy, visit us at

Professor Peter Stonier, Co-director of the Medical Affairs Certification program says:

Importance of Big Data for Medical Affairs Professionals

Hot Topics in Medical Affairs

The Importance of Big Data for Medical Affairs Professionals

How harnessing the power of big data can give Medical Affairs Professionals the strategic edge.

The most competitive companies in pharma must inundate themselves with data to navigate and excel in an ever increasingly complex environment. But, according to Bain & Company, companies have difficulty explaining the science and data to stakeholders in an effective and meaningful way.1 Just imagine a chemical engineer trying to explain chocolate milk to a 3-year-old. According to Bain research, this shortfall is one attributing factor to the 50% of launches that fail to meet company expectations.

So how does a company manage this problem without losing sight of their main goal, the resulting product? This is where a Medical Affairs Professional comes to the rescue. The ability for a Medical Affairs Professional to collect, analyze, interpret and present data can help ensure the success of a company.

Why is big data so important? Drug development has become more focused on narrower and more personal indications resulting in a more involved treatment. This trend, along with rising costs, and a greater multiplex for physicians to navigate has left a gap that leading companies are filling with medical affairs teams to help them translate their data in a way that physicians, payers, and providers can understand. While the company can focus on their products, they can leave the Medical Affairs Professionals to sort and distribute their big data in a valuable, effective, and consumable way.

Want to learn how to leverage company big data throughout the drug development process?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.

To read more about big data in the world of Medical Affairs please check out this great article from Bain & Company: Reinventing the Role of Medical Affairs.



  1. Plantevin L, Schlegel C, Gordian M. Reinventing the Role of Medical Affairs. Bain & Company. Published March 15, 2017. Accessed January 11, 2018.